

Fujifilm to establish first Bio-CDMO site in Japan

10 October 2022 | News

Accelerating business growth of the life sciences field and contributing to the strengthening of domestic vaccine production in Japan



Fujifilm Corporation has announced that it will establish the company's first Japanese Bio-CDMO (contract development and manufacturing organisation) site in Toyama City, Toyama Prefecture. The new site will be invested by Fujifilm Toyama Chemical and will be operational in FY2026. It will apply advanced biotechnologies and know-how nurtured through Fujifilm's global business, which enables offering high-quality CDMO services. When an outbreak of infectious disease evolves into a pandemic, the site will strongly support pharmaceutical companies for development and delivery of domestic vaccines.

The Japanese Government is currently promoting the strengthening of domestic vaccine production to prepare against future pandemics. As part of this effort, the Japanese Government supports projects such as establishing sites with dual-use facilities capable of producing biopharmaceuticals to meet customer needs during normal times and switching to vaccine production during a pandemic.

Fujifilm's investment has been selected for the project of "Developing biopharmaceutical manufacturing sites to strengthen vaccine production" promoted by the Ministry of Economy, Trade and Industry in Japan.

Fujifilm currently operates its own Bio-CDMO business globally, as well as drug discovery, development and manufacturing support, and offering culture media, cells and research reagents through a company-wide strategy led Fujifilm's Life Sciences Strategy Headquarters. By leveraging Fujifilm's global manufacturing sites and sales networks, the company has been expanding its business in the life sciences field mainly in Europe and the United States.